{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCV", "query": { "intervention": "PCV" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 159, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCV&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T13:51:22.938Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00991328", "title": "Role of Absolute Cerebral Oximetry to Prevent Neurocognitive Injury in Elderly Patients Undergoing Cardiac Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Post-Operative Delirium", "Postoperative Cognitive Dysfunction" ], "interventions": [ { "name": "SctO2 < 60 %.", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 15, "start_date": "2009-09", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2016-09-16", "last_synced_at": "2026-09-03T13:51:22.938Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00991328" }, { "nct_id": "NCT05158140", "title": "Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infection" ], "interventions": [ { "name": "V110", "type": "BIOLOGICAL" }, { "name": "V114", "type": "BIOLOGICAL" }, { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "Placebo for V110", "type": "BIOLOGICAL" }, { "name": "Placebo for V114", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 850, "start_date": "2022-01-12", "completion_date": "2023-02-21", "has_results": true, "last_update_posted_date": "2025-07-18", "last_synced_at": "2026-09-03T13:51:22.938Z", "location_count": 42, "location_summary": "North Hollywood, California • Northridge, California • Paramount, California + 38 more", "locations": [ { "city": "North Hollywood", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Paramount", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05158140" }, { "nct_id": "NCT02478684", "title": "Delayed Cord Clamping in Preterm Neonates", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Premature Birth of Newborn", "Infant, Very Low Birth Weight", "Delayed Separation of Umbilical Cord", "Placental Transfusion" ], "interventions": [ { "name": "30 Seconds of placental blood transfusion", "type": "OTHER" }, { "name": "60 Seconds of placental blood transfusion", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "28 Weeks", "maximum_age": "35 Weeks", "sex": "ALL", "summary": "28 Weeks to 35 Weeks" }, "enrollment_count": 105, "start_date": "2015-07", "completion_date": "2019-03-30", "has_results": false, "last_update_posted_date": "2019-10-30", "last_synced_at": "2026-09-03T13:51:22.938Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02478684" }, { "nct_id": "NCT02914184", "title": "Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infections, Rotavirus", "Rotavirus Vaccines" ], "interventions": [ { "name": "HRV PCV-free liquid vaccine", "type": "BIOLOGICAL" }, { "name": "Rotarix", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 1612, "start_date": "2016-10-27", "completion_date": "2018-11-26", "has_results": true, "last_update_posted_date": "2020-07-21", "last_synced_at": "2026-09-03T13:51:22.938Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Anaheim, California • Paramount, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Paramount", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02914184" }, { "nct_id": "NCT05844423", "title": "Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pneumococcal Vaccines" ], "interventions": [ { "name": "0.5 ml dose of 1.1 mcg VAX-24", "type": "BIOLOGICAL" }, { "name": "0.5 ml dose of PCV20", "type": "BIOLOGICAL" }, { "name": "0.5 ml dose of 2.2 mcg VAX-24", "type": "BIOLOGICAL" }, { "name": "0.5 ml dose of 2.2/4.4 mcg VAX-24", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vaxcyte, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "89 Days", "sex": "ALL", "summary": "42 Days to 89 Days" }, "enrollment_count": 802, "start_date": "2023-03-29", "completion_date": "2025-08-25", "has_results": false, "last_update_posted_date": "2025-09-11", "last_synced_at": "2026-09-03T13:51:22.938Z", "location_count": 32, "location_summary": "Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Madera", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Bardstown", "state": "Kentucky" }, { "city": "Haughton", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05844423" }, { "nct_id": "NCT00861744", "title": "Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rubella", "Mumps", "Measles", "Measles-Mumps-Rubella Vaccine" ], "interventions": [ { "name": "GSK Biological's investigational vaccine 209762", "type": "BIOLOGICAL" }, { "name": "M-M-R® II (Merck and Co)", "type": "BIOLOGICAL" }, { "name": "Varivax®", "type": "BIOLOGICAL" }, { "name": "Havrix®", "type": "BIOLOGICAL" }, { "name": "Prevnar®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 1259, "start_date": "2009-06-03", "completion_date": "2012-06-18", "has_results": true, "last_update_posted_date": "2020-01-03", "last_synced_at": "2026-09-03T13:51:22.938Z", "location_count": 45, "location_summary": "Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Conway", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861744" }, { "nct_id": "NCT03989271", "title": "Biological Effects of Quercetin in COPD", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Quercetin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Temple University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 29, "start_date": "2019-10-01", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2023-08-16", "last_synced_at": "2026-09-03T13:51:22.938Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03989271" }, { "nct_id": "NCT07446998", "title": "Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity & Overweight", "Mobility Disability", "HOMA-IR" ], "interventions": [ { "name": "Enobosarm", "type": "DRUG" }, { "name": "Semaglutide (Wegovy) weekly injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veru Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "65 Years to 100 Years" }, "enrollment_count": 200, "start_date": "2026-03-26", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-03T13:51:22.938Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Doral, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Doral", "state": "Florida" }, { "city": "Doral", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07446998" }, { "nct_id": "NCT06550011", "title": "Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neovascular (Wet) AMD" ], "interventions": [ { "name": "ABI-110 Low Dose", "type": "DRUG" }, { "name": "ABI-110 Medium Dose", "type": "DRUG" }, { "name": "ABI-110 High Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avirmax Biopharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 18, "start_date": "2024-08-07", "completion_date": "2031-01-16", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-03T13:51:22.938Z", "location_count": 4, "location_summary": "Bakersfield, California • Walnut Creek, California • San Antonio, Texas + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "San Antonio", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06550011" }, { "nct_id": "NCT06622057", "title": "D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "D07001-Softgel Capsules", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Capecitabine", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "InnoPharmax Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2026-06-09", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-03T13:51:22.938Z", "location_count": 3, "location_summary": "Tucson, Arizona • Miami Beach, Florida • Cleveland, Ohio", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06622057" } ] }